![Building on the Immunotherapy Foundation for Head and Neck Cancer: Lessons Learned, Practical Guidance, and Next Steps in Care](/_next/image?url=https%3A%2F%2Fcoatconnect-files.s3.amazonaws.com%2FDev%2FCover-6d9b9d9f-01b7-441a-a136-24713e0a9604-26c250f2-f6d1-431f-963c-a26ebfec0eaf-young-female-doctor-posing-corridor-hospital_1920X1080.webp%3FAWSAccessKeyId%3DAKIAJTMHAFAXQLGGIHMA%26Expires%3D1804066286%26Signature%3DMHxWXN0KPQDaIjCNRpp8jy4w%252BRE%253D&w=3840&q=75)
Building on the Immunotherapy Foundation for Head and Neck Cancer: Lessons Learned, Practical Guidance, and Next Steps in Care
Building on the Immunotherapy Foundation for Head and Neck Cancer: Lessons Learned, Practical Guidance, and Next Steps in Care is organized by PVI, PeerView Institute for Medical Education.
Activity Release Date: June 2, 2023
Activity Expiration Date: July 1, 2024
Activity Description:
Immune checkpoint inhibitors have transformed the frontline management of recurrent/metastatic head and neck cancer (HNC)—but how can oncology professionals build on that foundation to expand the therapeutic applications of immunotherapy in HNC? This “MasterClass & Case Forum” activity, taken from a recent live event, features a panel of leading HNC experts sharing case-based insights on clinical decision-making with immunotherapy in recurrent/metastatic disease and beyond. Developed in collaboration with the Head and Neck Cancer Alliance (HNCA), each case-centric session also features the latest evidence on established and emerging immune-based treatments, combinational and sequential approaches, and the potential of checkpoint blockade in resectable and locally advanced disease.
Educational Objectives:
Upon completion of this activity, participants should be better able to:
• Cite the latest clinical evidence and guideline recommendations supporting the use of checkpoint inhibitors and other immunotherapy options for the management of HNC
• Develop individualized treatment plans that incorporate checkpoint inhibitors and other immune modalities, including innovative combinational platforms, for the management of resectable, locally advanced, or recurrent/metastatic HNC
• Address practical aspects of care when using immunotherapy options, including provision of patient education and management of symptoms and immune-related AEs.